Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 205

Sort by

Sort Order Select

Journal Articles

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia

Yuchen Liu, Dominique R Bollino, Osman M Bah, Erin T Strovel, Tien Van Le, Jinoos Zarrabi, Sunita Philip, Rena G Lapidus, Maria R Baer, Sandrine Niyongere, Vu H. Duong, Christine C Dougherty, Jan Hendrik Beumer, Katherine D Caprinolo, Farin Kamangar, Ashkan Emadi

Blood blood.2024024837.

https://doi.org/10.1182/blood.2024024837

Published: 2024

Includes: Supplemental data

Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts

Blood (2023) 142 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2023-187861

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)

Yuchen Liu, Dominique Bollino, Osman M Bah, Erin T Strovel, Jinoos Zarrabi, Sunita Philip, Ezzat Mostafa, Rena G Lapidus, Maria R. Baer, Sandrine Niyongere, Vu H. Duong, Christine C Dougherty, Katherine Caprinolo, Ashkan Emadi

Blood (2023) 142 (Supplement 1): 60.

https://doi.org/10.1182/blood-2023-186244

Published: 2023

Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2023-187044

Published: 2023

Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blood (2023) 142 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2023-187383

Published: 2023

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Blood (2023) 142 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2023-185135

Published: 2023

Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2023-181886

Published: 2023

Journal Articles

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Blood (2023) 142 (Supplement 1): 5933.

https://doi.org/10.1182/blood-2023-179609

Published: 2023

Journal Articles

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Blood (2023) 142 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2023-188892

Published: 2023

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Jorge Cortes, Jay Yang, Sangmin Lee, Shira N. Dinner, Eunice S. Wang, Maria R. Baer, William B. Donnellan, Justin M. Watts

Blood (2023) 142 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2023-187404

Published: 2023

Journal Articles

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Guillermo Garcia-Manero, Olatoyosi Odenike, Shaun Fleming, Gail J. Roboz, Meagan Jacoby, Ilona Cunningham, Karl-Anton Kreuzer, Anoop K Enjeti, Maria R. Baer, Rachel Cook, Joseph Jurcic, Grace Ku, Ying Zhou, David Hoffman, Jalaja Potluri, Jacqueline S. Garcia

Blood (2023) 142 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2023-187102

Published: 2023

Journal Articles

Long-Term Follow-up and T Cell Characteristics of Patients with ASXL1 -Mutated Relapsed or Refractory MDS or CMML Treated with Guadecitabine and Atezolizumab

Casey L. O'Connell, Maria R. Baer, Vu H. Duong, Andreas Due Ørskov, Jakob Werner Hansen, Sunil Kumar Saini, Denice Tsao-Wei, Justin Cheng, Peter A. Jones, Kirsten Grønbæk

Blood (2023) 142 (Supplement 1): 1883.

https://doi.org/10.1182/blood-2023-189486

Published: 2023

Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Blood (2023) 142 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2023-187744

Published: 2023

Journal Articles

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Blood (2023) 141 (3): 295–308.

https://doi.org/10.1182/blood.2022016916

Published: 2023

Includes: Supplemental data

Journal Articles

Modified and Novel Lorrca Oxygenscan Measurement Parameters with Physiological Relevance

Stephen C Rogers, Zohreh Safari, Mary Brummet, Qihong Wang, Joy Okhuevbie, Nicole Glynn-Cunningham, Jennie Y. Law, Maria R. Baer, Allan Doctor

Blood (2022) 140 (Supplement 1): 8241–8242.

https://doi.org/10.1182/blood-2022-170649

Published: 2022

Journal Articles

Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)

Nadeen Anabtawi, Jessica Kohlschmidt, Daelynn Buelow, Shelley Orwick, Kennedy Coleman, Krzysztof Mrózek, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Maria R. Baer, John C. Byrd, Wendy Stock, Geoffrey L. Uy, Ann-Kathrin Eisfeld, Sharyn Baker, James S. Blachly

Blood (2022) 140 (Supplement 1): 6244–6246.

https://doi.org/10.1182/blood-2022-171222

Published: 2022

Journal Articles

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Blood (2022) 140 (Supplement 1): 3158–3161.

https://doi.org/10.1182/blood-2022-158248

Published: 2022

Journal Articles

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa, Jessica K. Altman, Pau Montesinos, Mrinal M. Patnaik, James M. Foran, Stephane De Botton, Maria R. Baer, Gary J. Schiller, Roland B. Walter, Marina Kremyanskaya, Kristen M. Pettit, Stephen A Strickland, Blake Tomkinson, Marilyn Tabachri, Mollie Leoni, Stephen Dale, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 153–156.

https://doi.org/10.1182/blood-2022-167412

Published: 2022

Journal Articles

Prognostication of the 2016-Who AML with Myelodysplasia-Related Changes Subclass and Mutations in MDS-Related Genes Using the 2022 European Leukemianet Risk Classification: A Retrospective Study

Fahad Alkaabba, Matthew Williams, Elizabeth Corley, Hanan Alharthy, Kathryn A.F. Kline, Seung Tae Lee, Michael Kallen, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Moaath K. Mustafa Ali

Blood (2022) 140 (Supplement 1): 3237–3238.

https://doi.org/10.1182/blood-2022-170531

Published: 2022

NARROW

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Long-Term Follow-up and T Cell Characteristics of Patients with ASXL1 -Mutated Relapsed or Refractory MDS or CMML Treated with Guadecitabine and Atezolizumab

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Modified and Novel Lorrca Oxygenscan Measurement Parameters with Physiological Relevance

Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Prognostication of the 2016-Who AML with Myelodysplasia-Related Changes Subclass and Mutations in MDS-Related Genes Using the 2022 European Leukemianet Risk Classification: A Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only